Plain-English translation of NCT04444869 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating HPV-positive oropharyngeal cancer (a type of throat cancer) by using lower doses of radiation therapy combined with cisplatin chemotherapy. People with this type of cancer tend to respond very well to treatment and have good long-term survival, but the standard radiation doses can cause lasting side effects like dry mouth and difficulty swallowing. Researchers want to see if reducing the radiation dose to lymph nodes that don't show signs of cancer can work just as well while causing fewer long-term problems.
Many patients treated for HPV-positive throat cancer live for many years afterward, but they often struggle with lasting side effects from standard radiation therapy. This trial exists to find out whether using lower radiation doses can control the cancer just as effectively while improving patients' quality of life in the years after treatment.
If you join this trial, you will receive concurrent chemotherapy (cisplatin) and radiation therapy as your primary treatment. The main difference from standard care is that you will receive a lower radiation dose to lymph nodes that do not show signs of cancer, while receiving standard doses to areas with visible disease. You will have regular follow-up appointments to monitor your response to treatment and watch for any side effects, with particular attention to dry mouth and swallowing difficulties.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States